Search Results

You are looking at 101 - 110 of 853 items for :

  • Refine by Access: All x
Clear All
Full access

Stereotactic Radiosurgery and Bevacizumab for Recurrent Glioblastoma Multiforme

Alvin R. Cabrera, Kyle C. Cuneo, James J. Vredenburgh, John H. Sampson, and John P. Kirkpatrick

locally, with 90% of relapses occurring within 2 cm of the original tumor. 4 As reflected in the NCCN Clinical Practice Guidelines in Oncology for Central Nervous System Cancers, therapies are variable and depend on the extent of recurrence and the

Full access

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Lynn Wilson, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar

criteria for a CR or PR are considered to have stable disease. Relapse is defined as evidence of disease progression 6 months or more after an initial CR or PR. Refractory disease is defined as failure to experience a response or experiencing disease

Full access

Modification and Implementation of NCCN Guidelines™ on Breast Cancer in the Middle East and North Africa Region

Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar

cancer. BMC Cancer 2006;6:194; and Elkum N, Dermime S, Ajarim D, et al. Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer 2007;7:222. Based on international

Full access

Postconsolidation Maintenance and Monitoring in Patients With Acute Promyelocytic Leukemia

Chezi Ganzel, Dan Douer, and Martin S. Tallman

Era ATO is considered the most potent anti-APL agent. Its use, which was traditionally reserved for patients experiencing relapse, has expanded and become more a part of induction-consolidation therapy. 15 , 16 Recently, primary results of the APL

Full access

Management of Extramedullary Leukemia as a Presentation of Acute Myeloid Leukemia

Samuel J. Slomowitz and Paul J. Shami

, chloroma , or myeloblastoma ), leukemia cutis (LC), and central nervous system (CNS) disease. Extramedullary disease at presentation or relapse can pose unique clinical problems. In general, the basic principles of systemic therapy remain the same. The

Full access

A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer

Kazuki Sudo, Xuemei Wang, Lianchun Xiao, Roopma Wadhwa, Hironori Shiozaki, Elena Elimova, David C. Rice, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Adarsh Hiremath, Nikolaos Charalampakis, Ritsuko Komaki, Mariela A. Blum, Stephen G. Swisher, Dipen M. Maru, Heath D. Skinner, Jeana L. Garris, Jane E. Rogers, Wayne L. Hofstetter, and Jaffer A. Ajani

Background Among patients with localized esophageal cancer (LEC), 35% or more develop distant metastases (DM) as first relapse, most in the first 24 months after local therapy. 1 Worldwide, yearly new cases of esophageal cancer are estimated

Full access

Improving Health Equity and Reducing Disparities in Pediatric and Adolescent/Young Adult Oncology: In Support of Clinical Practice Guidelines

Justine M. Kahn and Melissa Beauchemin

– 3 Hodgkin lymphoma (HL) represents an ideal paradigm for understanding cancer disparities, because successful treatments are well established in both the up-front and relapse treatment settings. Today, 5-year overall survival (OS) rates for children

Full access

Chimeric Antigen Receptor T-Cell Therapy

Ndiya Ogba, Nicole M. Arwood, Nancy L. Bartlett, Mara Bloom, Patrick Brown, Christine Brown, Elizabeth Lihua Budde, Robert Carlson, Stephanie Farnia, Terry J. Fry, Morgan Garber, Rebecca A. Gardner, Lauren Gurschick, Patricia Kropf, Jeff J. Reitan, Craig Sauter, Bijal Shah, Elizabeth J. Shpall, and Steven T. Rosen

later. 4 , 11 , 12 CD19 CAR T-Cell Therapy and Disease Management Leukemias Prognosis and overall survival (OS) rates in adult and pediatric patients with relapsed and refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. 13 – 15

Full access

Chemotherapy in the Management of Osteosarcoma and Ewing's Sarcoma

Scott M. Schuetze

. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity . N Engl J Med 1986 ; 314 : 1600 – 1606 . 19. Rosen G Caparros B Huvos AG . Preoperative chemotherapy for osteogenic sarcoma

Full access

Monitoring Chronic Myelogenous Leukemia in the Age of Tyrosine Kinase Inhibitors

Jerald P. Radich and Vivian Oehler

phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse . Leukemia 2005 ; 19 : 507 – 512 . 21. Merx K Muller MC Kreil S . Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic